Oxford Biomedica plc (LON:OXB)
London · Delayed Price · Currency is GBP · Price in GBX 853.00
-22.00 (-2.51%)
Jan 22, 2026, 4:35 PM GMT
Oxford Biomedica Revenue
Oxford Biomedica had revenue of 73.22M GBP in the half year ending June 30, 2025, with 70.04% growth. This brings the company's revenue in the last twelve months to 151.21M, up 55.44% year-over-year. In the year 2024, Oxford Biomedica had annual revenue of 128.80M with 43.84% growth.
Revenue (ttm)
151.21M
Revenue Growth
+55.44%
P/S Ratio
6.99
Revenue / Employee
168.02K
Employees
850
Market Cap
1.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 128.80M | 39.26M | 43.84% |
| Dec 31, 2023 | 89.54M | -50.45M | -36.04% |
| Dec 31, 2022 | 139.99M | -2.81M | -1.97% |
| Dec 31, 2021 | 142.80M | 55.07M | 62.77% |
| Dec 31, 2020 | 87.73M | 23.67M | 36.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genus | 672.80M |
| Oxford Nanopore Technologies | 204.69M |
| hVIVO | 54.47M |
| Bioventix | 13.12M |
| Scancell Holdings | 4.71M |
| PureTech Health | 4.66M |
| SkinBioTherapeutics | 4.64M |
| 4basebio | 1.78M |
Oxford Biomedica News
- 8 days ago - UK's Oxford Biomedica confirms unsolicited bid from funds managed by EQT - Reuters
- 2 months ago - Oxford Biomedica plc (OXBDF) Presents at Jefferies London Healthcare Conference 2025 - Slideshow - Seeking Alpha
- 3 months ago - Oxford Biomedica Acquires $4.5 Mln North Carolina Gene Therapy Facility - Nasdaq
- 4 months ago - Oxford BioMedica PLC (OXBDF) (H1 2025) Earnings Call Highlights: Strong Revenue Growth and ... - GuruFocus
- 4 months ago - Half Year 2025 Oxford Biomedica PLC Earnings Call Transcript - GuruFocus
- 4 months ago - Oxford Biomedica plc (OXBDF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Oxford Biomedica plc 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 6 months ago - UK's Oxford Biomedica maintains annual outlook - Reuters